In a patient with stabilized suicidal ideation and major depressive disorder who is currently taking mirtazapine (Remeron) 30 mg nightly, trazodone 50 mg at bedtime, and gabapentin 100 mg three times daily for anxiety, what medication should be added or adjusted to further manage the depression?

Add an SSRI or SNRI as Primary Antidepressant Treatment

For this patient with stabilized suicidal ideation and inadequately treated MDD on mirtazapine 30mg, trazodone 50mg, and gabapentin 100mg TID, you should add a second-generation antidepressant—specifically an SSRI (such as sertraline or escitalopram) or SNRI (such as venlafaxine)—as the current regimen lacks a primary antidepressant with proven efficacy for MDD. 1, 2

Rationale for Adding an SSRI/SNRI

The current medication regimen consists of:

• Mirtazapine 30mg: Primarily used for sleep/appetite, with antidepressant properties but often insufficient as monotherapy
• Trazodone 50mg: Low dose, primarily functioning as a sleep aid rather than therapeutic antidepressant dose
• Gabapentin 100mg TID: For anxiety, but not an evidence-based treatment for MDD

This patient essentially lacks a first-line antidepressant for MDD. Guidelines consistently recommend second-generation antidepressants (SSRIs, SNRIs) as first-line pharmacotherapy for major depression 1, 2. The evidence does not support clinically significant differences in efficacy among SSRIs and SNRIs, so selection should be based on adverse effect profiles, cost, and patient preferences 1.

Specific Medication Recommendations

First Choice: Sertraline or Escitalopram

• Sertraline: Start 50mg daily, titrate to 100-200mg as tolerated
• Escitalopram: Start 10mg daily, titrate to 10-20mg as tolerated

Rationale: Both have favorable tolerability profiles and extensive evidence for efficacy in MDD 1. Escitalopram/citalopram may have the least CYP450 interactions compared to other SSRIs, reducing drug-drug interaction concerns with the current regimen 3.

Alternative: Venlafaxine XR

• Start 37.5-75mg daily, titrate to 150-225mg daily as tolerated

Rationale: Some evidence suggests venlafaxine may be superior to SSRIs in treatment-resistant depression 1, though this patient hasn't yet had an adequate trial of a first-line agent.

Critical Safety Considerations with Current Regimen

Serotonin Syndrome Risk

You must monitor closely for serotonin syndrome when adding an SSRI/SNRI to mirtazapine 3, 4. The combination increases serotonergic activity through multiple mechanisms. Start at low doses and titrate slowly, monitoring especially in the first 24-48 hours after dosage changes 3.

Watch for: agitation, confusion, tachycardia, hypertension, hyperthermia, tremor, hyperreflexia, diaphoresis, mydriasis, or GI symptoms 4.

Suicidality Monitoring

Close monitoring for worsening suicidal ideation is mandatory, particularly in the first 1-2 weeks and after dose changes 1. SSRIs are associated with increased risk of nonfatal suicide attempts (OR 1.57-2.25) compared to placebo 1. Given this patient's recent suicidal ideation, assess weekly initially.

Specific Drug Considerations

• Avoid paroxetine: Higher rates of sexual dysfunction and discontinuation syndrome 3, 1
• Avoid citalopram >40mg/day: QT prolongation risk 3
• Consider bupropion as alternative: Lower sexual dysfunction rates 1, and evidence suggests bupropion combined with escitalopram may be particularly effective for reducing suicidal ideation 5

Treatment Algorithm

Week 0-2:

• Add SSRI/SNRI at starting dose
• Continue current medications unchanged
• Weekly monitoring for suicidality, serotonin syndrome, and treatment response 1

Week 2-6:

• Titrate SSRI/SNRI to therapeutic dose as tolerated
• Monitor every 1-2 weeks 1

Week 6-8:

• If inadequate response: Modify treatment (increase dose, switch, or augment) 1
• If partial response: Continue current regimen, reassess at 12 weeks
• If good response: Continue for 4-9 months minimum 1

Addressing the Current Regimen

Consider Optimizing Doses

• Mirtazapine 30mg: This is a therapeutic dose; could increase to 45mg if sedation/weight gain tolerable
• Trazodone 50mg: This is subtherapeutic for depression (therapeutic range 150-400mg) 6. If used solely for sleep, current dose is appropriate
• Gabapentin 100mg TID: This is a very low dose (300mg total daily). Therapeutic doses for anxiety are typically 900-3600mg/day 7. However, gabapentin lacks strong evidence for anxiety in MDD and is not guideline-recommended 1

Alternative Strategy: Combination Therapy

If you prefer combination therapy from the start, evidence supports mirtazapine combined with an SSRI or venlafaxine 8, 9. Recent research shows mirtazapine plus sertraline is highly effective 9, and this builds on the patient's current mirtazapine regimen.

Common Pitfalls to Avoid

1. Don't rely on mirtazapine alone at 30mg as adequate antidepressant monotherapy—it's often insufficient
2. Don't mistake trazodone 50mg for antidepressant therapy—this is a hypnotic dose
3. Don't continue gabapentin indefinitely without evidence of benefit for anxiety in this context
4. Don't wait beyond 6-8 weeks to modify treatment if response is inadequate 1
5. Don't abruptly discontinue any medication—taper to avoid discontinuation syndrome, particularly with shorter-acting SSRIs 3

Expected Timeline

• Week 1-2: Initial improvement possible, particularly with mirtazapine combinations 10
• Week 4-6: Full therapeutic effect expected 1, 6
• Week 6-8: Decision point for treatment modification if inadequate response 1

Significant improvement within the first 2 weeks is highly predictive of final response 10, so early assessment guides whether to continue, increase dose, or switch strategies.